



Universiteit
Leiden
The Netherlands

Personalized medicine in rheumatoid arthritis

Eektimmerman, F.

Citation

Eektimmerman, F. (2022, May 11). *Personalized medicine in rheumatoid arthritis*. Retrieved from <https://hdl.handle.net/1887/3303689>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3303689>

Note: To cite this publication please use the final published version (if applicable).

Personalized medicine in rheumatoid arthritis

Frank Eektimmerman

The research presented in this thesis was performed at the department of Rheumatology and the department of Clinical Pharmacy and Toxicology of Leiden University Medical Center, Leiden, The Netherlands.

Financial support for publication of this thesis was provided by departmental funds from the department of Clinical Pharmacy & Toxicology of the Leiden University Medical Center, Leiden, the Netherlands.

Cover	Paulien Frederiek Lipman
Layout	Renate Siebes Proefschrift.nu
Printed by	Proefschriftmaken.nl De Bilt
ISBN	978-94-90791-89-6

© F. Eektimmerman 2022

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage or retrieval system, without permission in writing from the author.

Personalized medicine in rheumatoid arthritis

Proefschrift

ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr.ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op woensdag 11 mei 2022
klokke 16.15 uur

door

Frank Eektimmerman

geboren te Almelo
in 1987

Promotor	Prof.dr. H.-J. Guchelaar
Copromotores	Dr. J.J. Swen Dr. C.F. Allaart
Promotiecommissie	Prof.dr. T. van Gelder Prof.dr. A.H.M. van der Helm - van Mil Prof.dr. E.N. van Roon (University of Groningen, Groningen) Prof.dr. J.G.W. Kosterink (University of Groningen, Groningen) Dr. M. Teichert

Chapter 1	General introduction	7
Chapter 2	Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review <i>Pharmacogenomics J. 20, 159–168 (2020)</i>	19
Chapter 3	<i>SLC04A1, SLC22A2</i> and <i>SLC28A2</i> variants not related to methotrexate efficacy or toxicity in rheumatoid arthritis patients <i>Pharmacogenomics 19(7), 613–619 (2018)</i>	47
Chapter 4	Validation of a clinical pharmacogenetic model to predict methotrexate non-response in rheumatoid arthritis patients <i>Pharmacogenomics 20(2), 85–93 (2019)</i>	59
Chapter 5	Genome-wide association analysis of methotrexate-induced liver injury in rheumatoid arthritis patients <i>Submitted</i>	79
Chapter 6	Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis <i>Pharmacogenomics 18(10), 945–953 (2017)</i>	95
Chapter 7	General discussion	113
Chapter 8	English summary	125
	Nederlandse samenvatting	128
	Curriculum vitae	133
	Dankwoord	137